Vyrex Corporation

Other

Pcb Associates, Inc.

Uyrex Corporation

Biodor U.S. Holding

Sheldon S Hendler

Robert A Sanchez

Jan Zielinski

Dusan Miljkovic

Mark F McCarty

Toyoshi Inoguchi

David Michael Rorvik

Tara

Phycobilins are disclosed to have prodrug activity as inhibitors of NADPH oxidase activity and are disclosed to be useful in the prophylaxis and/or treatment of medical conditions associated with or linked to an NADPH oxidase activity. Compositions containing phycobilins are described which facilitate the administration of phycobilins.

Compositions for inhibiting NADPH oxidase activity

Isoflavones are modified by esterification at one or more of the C4', C5, C6, and C7 positions to promote bioavailability, and especially to enhance solubility over the corresponding unesterified isoflavones. Preferred modifications produce a carboxylic acid hemiester or a phosphate ester which is biologically hydrolysable. Preferred starting isoflavones are genistin and daidzin, and still more preferably comprises an aglycone form such as genistein or daidzein. Esterified isoflavones may be employed therapeutically or prophylactically for a variety of conditions, provided as a dietary supplement, or added to natural or processed food-stuffs. Further preferred uses include incorporation of contemplated compounds into topical formulations, and especially cosmetic topical formulations.

Isoflavone derivatives

Isoflavones are modified by esterification at one or more of the C &prime;, C , C , and C positions to promote bioavailability, and especially to enhance solubility over the corresponding unesterified isoflavones. Preferred modifications produce a carboxylic acid hemiester or a phosphate ester which is biologically hyrolyzable. Preferred starting isoflavones are genistin and daidzin, and still more preferably comprises an aglycone form such as genistein or daidzein. Esterified isoflavones may be employed therapeutically or prophylactically for a variety of conditions, provided as a dietary supplement, or added to natural or processed food-stuffs.

This invention provides esters of propofol (2,6-diisopropylphenol). The propofol esters are soluble in water and metabolize rapidly to propofol in the body. The propofol esters are useful as prodrugs for the same indications as propofol.

Water-soluble prodrugs of propofol for treatment of migrane

This invention provides esters of propofol (2,6,-diisoprophenol). The propofol esters are soluble in water and metabolize rapidly to propofol in the body. The propofol esters are useful as pro-drugs for the same indications as propofol. This invention also provides methods of treating neurodegenerative diseases by administering as effective amount of propofol.

Water soluble pro-drugs of propofol

A composition of matter which comprises a metallic complex of the formula

Metallic oligopeptide complexes

This invention relates to compounds, compositions, uses and methods for inhibiting viral and retroviral replication and for treating viral and retroviral infections via the administration of various compounds, including antioxidants, preferably compounds corresponding to the formula ##STR1## wherein n=1, 2, 3, or 4; m=0 or 1; X is O, S or CH.sub.2 ; R.sub.1 is hydrogen or tertiary butyl or lower alkyl of from one to six carbon atoms, inclusive; R.sub.2 is tertiary butyl or lower alkyl of from one to six carbon atoms, inclusive; and R.sub.3 is hydrogen or alkyl or aryl or mixed alkyl/aryl, containing a total of 5-25 carbon atoms.

Antiviral agents

This invention relates to use of cyclodextrins to complex urushiols to protect against and to treat irritation arising from exposure to urushiols. cyclodextrins, particularly gamma-cyclodextrins, are capable of binding strongly to urushiols and can be used effectively to prevent irritation of tissue that is exposed to urushiols. Cyclodextrin-urushiol complexes can also be used to desensitize against urushiol. Compositions containing cyclodextrin/urushiol complexes may be provided as tablets for buccal administration in dosages sufficient to induce desensitizing response.

Complexing urushiols

A lipophilic pharmaceutical formulation including a digestible vegetable oil and a phenolic antioxidant such as probucol is disclosed for oral administration. The probucol will typically be present in an amount of between 5 and about 15% by weight and the digestible vegetable oil will be present in an amount of between about 80 and 95% by weight. A small quantity of ethanol may be added to the formulation to increase the solubility of probucol. The formulations will be orally administered for treatment of hypercholesterolemic patients and others suffering from certain ailments.

Delivery formulation for probucol

Disclosed are methods for preventing free radical-induced oxidative damage and inflammatory response in biological tissue. The methods comprise exposing biological tissue to vapor-phase, phenolic antioxidants such as vaporized 2,6-diisopropylphenol.

Airborne protectants against oxidative tissue damage

This invention relates to use of cyclodextrins to complex urushiols to protect against and to treat irritation arising from exposure to urushiols. Cyclodextrins, particularly gamma-cyclodextrins, are capable of binding strongly to urushiols and can be used effectively to prevent irritation of tissue that is exposed to urushiols. Cyclodextrin-urushiol complexes can also be used to desensitize against urushiol. Compositions containing cyclodextrin/urushiol complexes may be provided as tablets for buccal administration in dosages sufficient to induce desensitizing response.

The present invention provides delipidating compositions containing essentially oil-free 'empty' cyclodextrin compositions. It also provides compositions for use in removal of cerumen from the ear. The compositions containing 'empty' cyclodextrin advantageously avoid use of harsh, drying agents or injurious mechanical methods.

Methods for delipidation of skin and cerumen removal

This invention relates to methods for delipidation of skin or hair through the use of cyclodextrins and cyclodextrin derivatives such as hydroxypropyl .beta.-cyclodextrin. The invention also relates to cerumen removal methods involving introduction of cyclodextrins to the ear canal, followed by complexation of the cyclodextrin with cerumen components, and removal of the resulting cyclodextrin complexes. The cyclodextrin components are used in a substantially oil-free powdered or aqueous formulation without detergents, soaps, solvents, oils or other lipid-like agents.

Growing community of inventors

La Jolla, CA, United States of America

Sheldon S Hendler